Listed

Bone Biologics Corp: Form 10-Q for the period ended Mar 31, 2021

Filed with the SEC on May 21, 2021 and accepted by EDGAR at May 21, 2021, 15:19 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-01-01 to 2021-03-31$1.07bnus-gaap:Revenues
Research and development3 months2021-01-01 to 2021-03-31$45.5kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-01-01 to 2021-03-31−$180.9kus-gaap:OperatingIncomeLoss
Net income3 months2021-01-01 to 2021-03-31−$431.7kus-gaap:NetIncomeLoss
Diluted EPS3 months2021-01-01 to 2021-03-31−$0.06us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2021-01-01 to 2021-03-31−$128.0kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2021-03-31$71.2kus-gaap:CashAndCashEquivalentsAtCarryingValue
Total assetsAt period end2021-03-31$71.2kus-gaap:Assets
Total liabilitiesAt period end2021-03-31$14.2mus-gaap:Liabilities
Shareholders' equityAt period end2021-03-31−$14.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-21-012491. Last ingested by Listed: Nov 11, 2026, 03:46 ET. Listed shows no prices and gives no investment advice.